

WashU Medicine Honors CEO Haruo Naito and Eisai for Longstanding Contributions to Alzheimer's Disease Research and Healthcare

Eisai Co., Ltd. (Headquarters: Tokyo, "Eisai") announced today that Washington University School of Medicine in St. Louis ("WashU Medicine") held a ceremony unveiling a plaque honoring the longstanding contributions and achievements of CEO Haruo Naito and Eisai in healthcare, including in the field of Alzheimer's disease (AD). The plaque, commemorating these achievements, will be permanently displayed on a wall in the lobby of the Jeffrey T. Fort Neuroscience Research Building (NRB).



From left: Jin-Moo Lee, Professor of Neurology and Chair, Department of Neurology; John Morris, Professor of Neurology and Co-Director of the Charles F. and Joanne Knight Alzheimer Disease Research Center (Knight ADRC); Haruo Naito, CEO of Eisai; Randall Bateman, Professor of Neurology and Principal Investigator and Co-Director, Dominantly Inherited Alzheimer Network (DIAN); Will Arvin, Vice Chancellor for Medical Advancement; David Holtzman, Professor of Neurology and Director, Knight ADRC

CEO Haruo Naito and Eisai were recognized for their long-term and significant contributions to WashU Medicine and the Knight Family Dominantly Inherited Alzheimer Network-Trials Unit (DIAN-TU), as well as for the profound impact CEO Naito's leadership and vision have had on patients, families and researchers around the world.

Eisai and WashU Medicine have been collaborating in research on neurodegenerative diseases, including dementia and Parkinson's disease. In particular, in the AD field, the Phase II/III Tau NexGen Study conducted by the Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU), led by the University's School of Medicine, is exploring the safety, tolerability, biomarkers and cognitive efficacy of Eisai's anti-MTBR (microtubule binding region) tau antibody etalantug (E2814) for the treatment of dominantly inherited Alzheimer's disease (DIAD). In this study, the anti-amyloid beta (A β) protofibril antibody lecanemab was selected as the backbone anti-amyloid therapy.

The collaboration between WashU Medicine neuroscience researchers and Eisai reinforces a shared mission of advancing human healthcare, which accelerates turning discoveries from medical research into solutions for patients, improving care for families today while working toward a future free of neurodegenerative disease.

Media Inquiries:
Public Relations Department,
Eisai Co., Ltd.
+81-(0)3-3817-5120

Haruo Naito Eisai



Haruo Naito has made transformative commitments to WashU Medicine and the Knight Family Dominantly Inherited Alzheimer Network-Trials Unit. His leadership and vision have had a profound impact on patients, families, and researchers around the world.

As representative corporate officer and CEO of Eisai, Haruo Naito has long championed patient-centric management grounded by his philosophy of *human health care*. Under his leadership, Eisai has developed innovative treatments for Alzheimer's disease and cancer while addressing global health challenges such as neglected tropical diseases. He has played a leading role in industry reform, advocating for sustainable systems that strengthen public health.

The collaboration between WashU Medicine neuroscience researchers and Eisai reinforces a shared mission of advancing human health. This partnership accelerates discoveries from bedside to bench, improving care for families today while working toward a future free of neurodegenerative disease.

The plaque unveiled at the ceremony